InVivo Therapeutics Holdings Corporation (NVIV) |
| 0.3207 -0.167 (-34.28%) 02-12 16:00 |
| Open: | 0.4081 |
| High: | 0.409 |
| Low: | 0.301 |
| Volume: | 1,609,868 |
| Market Cap: | 1(M) |
| PE Ratio: | -0.1 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 13.12 |
| Resistance 1: | 12.38 |
| Pivot price: | 11.50 |
| Support 1: | 11.18 |
| Support 2: | 9.30 |
| 52w High: | 2.4 |
| 52w Low: | 0.22 |
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI). Its primary investigational product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold. This device is engineered to be implanted directly at the site of injury within the spinal cord, aiming to treat acute SCI. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
| EPS | 0.800 |
| Book Value | 4.190 |
| PEG Ratio | 0.90 |
| Gross Profit | 18.306 |
| Profit Margin (%) | 10.68 |
| Operating Margin (%) | 17.64 |
| Return on Assets (ttm) | 5.5 |
| Return on Equity (ttm) | 9.9 |
Wed, 02 Sep 2026
InVivo Therapeutics Holdings Corp (NVIV) Peer Comparison – Compare with Others - Value Research
Tue, 06 Feb 2024
Why Is Trio Petroleum (TPET) Stock Down 38% Today? - InvestorPlace
Thu, 09 Mar 2023
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury - Business Wire
Tue, 11 Jul 2017
InVivo Therapeutics Appoints Richard Toselli, M.D. as Chief Medical Officer - citybuzz -
Mon, 30 Mar 2015
InVivo Therapeutics adds 4th clinical site - MassDevice
Thu, 03 Sep 2026
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |